Our Most Recent Episode
Digging deeper into high risk myeloma with Dr. Jesús San Miguel, MD, PhD, University of Navarra, Spain
Dr. Jesús San Miguel, MD, PhD University of Navarra, Spain Interview Date: October 3 Summary Dr. Jesús San Miguel describes his deep work for high risk myeloma patients. He starts by discussing the need for minimal residual disease testing – it avoids over or under-treating patients. When patients begin with myeloma treatment, they usually have […]
Calling All Musicians: New Music Contest to Support Myeloma Research!
Our new Songs for Life contest is in full swing to help raise funds for multiple myeloma research. Tell your musical friends and family to donate a song between now and November 15. Winners to be included on the Songs For Life 2015 album with all proceeds benefiting myeloma research. Spread the news today!
Our Next Episode
Our Next Show: Preventing Myeloma Bone Damage Using a New Compound with Dr. Irene Ghobrial, MD, PhD, Dana Farber Cancer Institute
Thursday, October 30, 9 am PDT, 10 am MDT, 11 am CDT, Noon EDT
Call In by Phone to Listen Live: (347) 637-2631 or
Bone damage is one of the most painful and deadly effects of multiple myeloma. Learn about a new compound that is in early clinical trials to make the bone marrow microenvironment unfriendly to the myeloma and prevent it from settling into the bones. Dr. Irene Ghobrial will describe her work on a new compound called SDF-1 (stromal cell-derived factor-1) which acts as a protein magnet, attracting certain cells to new locations within the bone marrow. This compound is now in early clinical trials and is showing that it can stop progression of the disease in the bones.
Dr. Irene M. Ghobrial, MD, PhD is an Associate Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. She is a physician Scientist who specializes in the field of Multiple Myeloma and Waldenstrom Macroglobulinemia, specifically in the precursor conditions of MGUS and Smoldering disease. She particularly focuses on the role of the malignant bone marrow niche in disease progression from early precursor conditions like MGUS/smoldering MM to overt MM. She uses MM as a model of bone metastasis and dissemination.
Dr. Ghobrial and her lab attempt to examine how MM can use a process of cell dissemination that is similar to cell trafficking of hematopoietic stem cell (HSCs) and cell metastasis in solid epithelial carcinomas. These studies can guide our understanding of the biological changes that occur during progression in MM.
In addition, her laboratory research data has been rapidly translated to innovative investigator-initiated clinical trials. They have conducted over 10 phase I and II clinical trials. Their studies on MM cell trafficking have been translated to the first chemosensitization trials in patients with Multiple Myeloma. In addition, she is the co-leader of the first consortium of clinical trials for blood cancers in collaboration with the Leukemia and Lymphoma Society to form the Blood Cancer Research Partnership (BCRP), a consortium for innovative clinical trials of 11 community oncology sites coordinated by DFCI. Moreover, She initiated a new clinic for Prevention of Progression in Blood Cancers where patients with precursor conditions such as MGUS, early MDS and early CLL will be monitored propsectively for clonal evolution during disease progression. Clinical trials and research efforts are coordinated for patients seen in this clinic to develop therapeutic agents that can prevent/delay disease progression in these early malignant conditions.
Our Previous Episodes
Extending Outcomes with Continuous Myeloma Maintenance: Dr. Antonio Palumbo, MD, University of Torino
Detecting myeloma relapse early - The new Hevylite® test can help with Dr. Stephen Harding of The Binding Site
What's new in MGUS? Very interesting ASCO findings and the diagnostics you need to have as an MGUS patient with Dr. Brendan Weiss, MD
The hopeful discovery of an engineered measles virus for myeloma treatment with Dr. Stephen Russell, MD, PhD
Where are we headed with new agents and transplant approaches in myeloma? Dr. Paul Richardson, MD, Dana-Farber Cancer Institute
A compelling European approach in myeloma care: Collaboration, Referrals and Established Guidelines with Dr. Pieter Sonneveld, MD, PhD, Erasmus MC
Myeloma is not a single disease: The illuminating discovery and implications for care with Dr. Michael Kuehl, MD, PhD of the NCI
Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission
Dr. Craig Crews of the Crews Laboratory at Yale University describes his discovery and development of carfilzomib (Kyprolis) and what it takes to get a new drug across the "Valley of Death"
Our Next Show: How does a drug begin as an idea and become an actual myeloma therapy in the clinic? Dr. Craig Crews, Crews Laboratory at Yale University discusses his discovery and development of carfilzomib (Kyprolis)
Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation
Dr. Benson describes how immunotherapy and NK cells work, and why most cancers are genetic or molecular diseases and not anatomical diseases
Dr. Michael Shapira, MD shares an early vaccine for myeloma and his work to raise the age ceiling for allo and auto transplants
Three myeloma themes with Dr. Robert Z. Orlowski of MD Anderson Cancer Center:Immunotherapy, making transplant better and using new small molecules for more convenient myeloma care
Dr. Leif Bergsagel, MD of the Mayo Clinic shares the impact of the MYC translocation in myeloma progression and relapse and a new target that boosts immunity while impacting myeloma cells
Genes that drive myeloma growth and why new discoveries of myeloma's complexities are hopeful with Dr. Jens Lohr, MD of The Broad Institute and Dana Farber Cancer Institute
Dr. Philip McCarthy of Roswell Park Cancer Institute on transplants: best induction therapies, best approaches for high risk and how patients can recover faster
Dr. Damian Green shares a new approach to combine two proven approaches (immunotherapy and radiation) to selectively target only active myeloma cells using the common CD38 protein
Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari.
Find a multiple myeloma specialist near you. We’ve moved this directory to the www.myelomacrowd.org site.